Skip to main content

Advertisement

SpringerLink
Log in

Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 12 August 2021

Abstract

The immunomodulatory effects of denosumab have raised concerns for risk of malignancy. This meta-analysis of 25 randomized controlled trials (21,523 patients) shows similar risk of malignancy between denosumab (60 mg every 6 months, up to 48 months) and any comparator. Post-marketing surveillance may detect rare or late-occurring drug effects. Possible increased risk of malignancy in patients treated with denosumab has been concerned due to inhibition of the immune modulator receptor activator of nuclear factor κ-Β ligand (RANKL). We aimed to assess the risk of malignancy associated with denosumab treatment. PubMed and Cochrane Central Register of Controlled Trials were searched up to May 27, 2019 to include all randomized controlled trials of denosumab (60 mg every 6 months) versus any comparator. Trials using higher drug doses for prevention of skeletal-related events were excluded. Data were independently extracted by two reviewers and analyzed using a fixed-effect model to pool risk ratios (RRs) with 95% confidence intervals (CI). Twenty-five trials (21,523 patients) were included. The risk of malignancy was similar between denosumab and other comparators (absolute risk difference 0%, RR 1.08 [95% CI, 0.93–1.24], I2 = 0%). Sensitivity analysis based on adequate allocation concealment showed similar results. The risk of malignancy did not differ between groups in any of the subgroup analyses, including stratification by race, individual comparators, indications for treatment, and longer drug exposure (≥ 24 months, 9 studies). The risk ratio of malignancy-related death was similar between groups. Early concerns about a potential increased risk of malignancy resulting from an immunomodulatory effect of denosumab are not supported by evidence from this meta-analysis of 25 RCTs with drug exposure of up to 48 months. Since RCTs with longer observation for safety outcomes are not expected, post-marketing surveillance will be the main means for detection of rare or late-occurring events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 22(2):435–446. https://doi.org/10.1007/s00198-010-1326-y

    Article  CAS  PubMed  Google Scholar 

  2. Terpos E, Dimopoulos MA (2011) Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunol Immunother 60(3):305–317. https://doi.org/10.1007/s00262-011-0974

    Article  CAS  PubMed  Google Scholar 

  3. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19(7):1059–1066. doi:https://doi.org/10.1097/PAT.0000000000000116

  4. Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S et al (2015) Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer Treat Rev 41(2):61–68. https://doi.org/10.1016/j.ctrv.2014.12.001

    Article  CAS  PubMed  Google Scholar 

  5. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 20 361(8):756–765. https://doi.org/10.1056/NEJMoa0809493

    Article  CAS  Google Scholar 

  6. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 22 5(7):513–523. https://doi.org/10.1016/S2213-8587(17)30138-9

    Article  CAS  Google Scholar 

  7. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2011) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Chichester (UK)

    Google Scholar 

  8. Friedrich JO, Adhikari NKJ, Beyene J (2007) Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 23(7):5. https://doi.org/10.1186/1471-2288-7-5

    Article  Google Scholar 

  9. Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D (2019) Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis 78(7):899–907. https://doi.org/10.1136/annrheumdis-2018-214827

    Article  CAS  PubMed  Google Scholar 

  10. Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2018) Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial. JBMR Plus 2(5):289–294. https://doi.org/10.1002/jbm4.1005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chen Q, Hu C, Liu Y, Song R, Zhu W, Zhao H, Nino A, Zhang F, Liu Y (2018) Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study. PLoS One 13(6):e0197984. https://doi.org/10.1371/journal.pone.0197984

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6(6):445–454. https://doi.org/10.1016/S2213-8587(18)30075-5

    Article  CAS  PubMed  Google Scholar 

  13. Szczepanek K, Pedziwiatr M, Klek S (2017) Denosumab improves bone mineral density in patients with intestinal failure receiving home parenteral nutrition: results from a randomized, controlled clinical trial. J Parenter Enter Nutr, 148607117695247. https://doi.org/10.1177/0148607117695247

  14. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163–3170. https://doi.org/10.1210/jc.2016-1801

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA (2016) Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab 101(4):1353–1363. https://doi.org/10.1210/jc.2015-4181

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433–443. https://doi.org/10.1016/S0140-6736(15)60995-3

    Article  CAS  PubMed  Google Scholar 

  17. Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433–443. https://doi.org/10.1016/S0140-6736(15)60995-3

    Article  CAS  Google Scholar 

  18. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99(7):2599–2607. https://doi.org/10.1210/jc.2013-4175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie S-AM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99(5):1694–1700. https://doi.org/10.1210/jc.2013-4440

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54. https://doi.org/10.1016/j.bone.2013.10.006

    Article  CAS  PubMed  Google Scholar 

  21. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54. https://doi.org/10.1016/j.bone.2013.10.006

    Article  CAS  Google Scholar 

  22. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161–3169. https://doi.org/10.1210/jc.2012-1569

    Article  CAS  PubMed  Google Scholar 

  23. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M (2012) Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 23:1131–1140. https://doi.org/10.1007/s00198-011-1786-8

    Article  CAS  PubMed  Google Scholar 

  24. Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22(6):1725–1735. https://doi.org/10.1007/s00198-010-1378-

    Article  CAS  PubMed  Google Scholar 

  25. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25(8):1886–1894. https://doi.org/10.1002/jbmr.81

    Article  PubMed  PubMed Central  Google Scholar 

  26. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TLJ, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755. https://doi.org/10.1056/NEJMoa0809003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, Martin JS, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25(1):72–81. https://doi.org/10.1359/jbmr.090716

    Article  CAS  PubMed  Google Scholar 

  28. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Álvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24(1):153–161. https://doi.org/10.1359/jbmr.0809010

    Article  CAS  PubMed  Google Scholar 

  29. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882. https://doi.org/10.1200/JCO.2008.16.3832

    Article  CAS  PubMed  Google Scholar 

  30. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222–229. https://doi.org/10.1016/j.bone.2008.04.007

    Article  CAS  PubMed  Google Scholar 

  31. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R, Denosumab Rheumatoid Arthritis Study Group (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299–1309. https://doi.org/10.1002/art.23417

    Article  CAS  PubMed  Google Scholar 

  32. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93(6):2149–2157. https://doi.org/10.1210/jc.2007-2814

    Article  CAS  PubMed  Google Scholar 

  33. Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J et al (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheum (Hoboken, NJ) 71(7):1174–1184. https://doi.org/10.1002/art.40874

    Article  CAS  Google Scholar 

  34. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50–56. https://doi.org/10.1016/S0140-6736(13)60856-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821–831. https://doi.org/10.1056/NEJMoa044459

    Article  CAS  PubMed  Google Scholar 

  36. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22(12):1832–1841. https://doi.org/10.1359/jbmr.070809

    Article  CAS  PubMed  Google Scholar 

  37. Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, Yuan FZ, Guo C, Yan SG (2012) Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 66(4):399–408. https://doi.org/10.1111/j.1742-1241.2011.02806.x

    Article  CAS  PubMed  Google Scholar 

  38. von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K, Goeree R, Tarride J-E, Xie F (2011) Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum 41(2):178–186. https://doi.org/10.1016/j.semarthrit.2011.03.005

    Article  CAS  Google Scholar 

  39. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E (2009) Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 41(10):721–729. https://doi.org/10.1055/s-0029-1224109

    Article  CAS  PubMed  Google Scholar 

  40. Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G, Cao X, Wang P (2014) Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol 7(5):2113–2122

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, Nigwekar SU, Leder BZ, Solomon DH (2019) Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 104(5):1753–1765. https://doi.org/10.1210/jc.2018-02236

    Article  PubMed  Google Scholar 

  42. Renema N, Navet B, Heymann M-F, Lezot F, Heymann D (2016) RANK-RANKL signalling in cancer. Biosci Rep 36(4). https://doi.org/10.1042/BSR20160150

  43. Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T (2004) Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 101(8):1794–1802. https://doi.org/10.1002/cncr.20550

    Article  CAS  PubMed  Google Scholar 

  44. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24(2):182–195. https://doi.org/10.1359/jbmr.081112

    Article  CAS  PubMed  Google Scholar 

  45. Chen F, Pu F (2016) Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat 39(7–8):453–459. https://doi.org/10.1159/000447372

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine A, Rabin Medical Center - Beilinson Hospital, 39 Jabotinski St., 4941492, Petach Tikva, Israel

    D. Rosenberg, T. Avni, A. Gafter-Gvili & T. Diker-Cohen

  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    T. Avni, G. Tsvetov, A. Gafter-Gvili & T. Diker-Cohen

  3. Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel

    G. Tsvetov & T. Diker-Cohen

Authors
  1. D. Rosenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Avni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Tsvetov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Gafter-Gvili
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Diker-Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Rosenberg.

Ethics declarations

Conflict of interest

We declare that there is no conflicts of intrest in our article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosenberg, D., Avni, T., Tsvetov, G. et al. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 32, 413–424 (2021). https://doi.org/10.1007/s00198-020-05704-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-020-05704-6

Keywords

Search

Navigation